Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12006469.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present the case of an elderly patient who died of fulminant hepatic failure in the course of receiving 2 months of treatment with pyrazinamide and rifampin for his latent tuberculosis. This 2-month course of treatment for latent tuberculosis is one of four options recently recommended by the Centers for Disease Control and Prevention. We discuss the safety of using this two-drug regimen to treat latent tuberculosis in stable elderly patients.
Medical subject headings
- Antibiotics, Antitubercular
- Antitubercular Agents
- Liver Failure
- Pyrazinamide
- Rifampin
- Tuberculosis, Pulmonary